Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Bevacizumab-awwb
Brand Name Mvasi
Payment Category Medicare Part B
Year Introduced 2017
Type of Drug Biosimilar vascular endothelial growth factor-specific angiogenesis inhibitor
Manufacturer Amgen
Medical Affairs Questions (date verified) 800.772.6436
Coverage & Reimbursement Questions 855.669.9360
HCPCS Q5107
Billing Unit 10 mg
Medicare Payment Limit (Effective January 1, 2021) $56.73

FDA-Approved Indication(s)

  • Indicated for 1) Metastatic colorectal cancer, with a) intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment, or b) fluoropyrimidine- irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen; 2) Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; 3) Recurrent glioblastoma in adults as a single agent; 4) Metastatic renal cell carcinoma with interferon alfa; and 5) Cervical cancer, in combination with paclitaxel and cisplatin or topotecan in persistent, recurrent, or metastatic disease. (6/25/19)

ICD-10 Code(s) for Labeled Indication(s) Colorectal cancers [C18.x, C19, C20,or C21.x, dependent on location]; Malignant neoplasm of bronchus and lung [C34.xx]; Malignant neoplasm of brain [C71.x]; Malignant neoplasm of kidney [C64.x] or renal pelvis [C65.x]; Malignant neoplasm of cervix uteri _[C53.x]
Name Strength Form Package Labeler NDC

Copyright © 2021 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US